Search

Displaying results 1471 - 1480 of 2430 in total
  1. Drug

    Rifalazil

    go.drugbank.com/drugs/DB04934
    Investigational

    Rifalazil is a derivative of the antibiotic rifamycin. It is being investigated by ActivBiotics for the treatment of various bacterial infections.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  2. Drug

    Lofexidine

    go.drugbank.com/drugs/DB04948
    ApprovedInvestigational

    Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  3. Drug

    Tipifarnib

    go.drugbank.com/drugs/DB04960
    Investigational

    Tipifarnib (R-115777) is a substance that is being studied in the treatment of acute myeloid leukemia (AML) and other types of cancer. It belongs to the family of drugs called farnesyltransferase inhibitors. It is also called Zarnestra. ...

    Categories: P-glycoprotein inhibitors
  4. Drug

    Belinostat

    go.drugbank.com/drugs/DB05015
    ApprovedInvestigational

    Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety ...

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  5. Drug

    Ganaxolone

    go.drugbank.com/drugs/DB05087
    ApprovedInvestigational

    Ganaxolone is the 3β-methylated synthetic analog of allopregnanolone, a metabolite of progesterone. Ganaxolone belongs to a class of compounds referred to as neurosteroids. Endogenous neurosteroids, which comprise certain metabolites of ...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 Substrates
  6. Drug

    Trabectedin

    go.drugbank.com/drugs/DB05109
    ApprovedInvestigational

    Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate Ecteinascidia turbinata and now produced synthetically. Trabectedin has a unique mechanism of action. I...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 Substrates
  7. Drug

    Pretomanid

    go.drugbank.com/drugs/DB05154
    ApprovedInvestigational

    Persistent forms of tuberculosis (TB) have proven to be a major cause of global morbidity and mortality and a cause for significant concern. Research in recent years has been geared toward the development of novel therapies that target p...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  8. Drug

    SQ-109

    go.drugbank.com/drugs/DB05186
    Investigational

    SQ-109 is an orally active, small molecule antibiotic for treatment of pulmonary TB. Currently in Phase I clinical trials, SQ-109 could replace one or more drugs in the current first-line TB drug regimen, simplify therapy, and shorten th...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 Substrates
  9. Drug

    Bezisterim

    go.drugbank.com/drugs/DB05212
    Investigational

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  10. Drug

    Hepatitis B immune globulin

    go.drugbank.com/drugs/DB05276
    ApprovedInvestigational

    Long-term hepatitis B immune globulin (HBIG) has been shown to reduce hepatitis B virus (HBV) reinfection in patients transplanted for hepatitis B. Infection with hepatitis B may lead to hepatocellular carcinoma, a type of liver cancer. ...

    Products: HEPATITIS B IMMUNOGLOBULIN P BEHRING, HEPATITIS B IMMUNOGLOBULIN P BEHRING 1000 IU/5 ML IM KULLANIMA HAZIR ENJEKTÖRDE ENJEKSİYONLUK ÇÖZELTİ